Interesting info...Larry to present in May 2016
1:30 pm INTREPID-2566 : A Phase II Clinical Trial of NNZ-2566 (trofinetide) in Moderate to Severe TBI
Overview of the methodology, endpoints and analytical methodology for the INTREPID-2566 trial and preliminary findings, if available. The presentation will emphasize the role of biomarkers in the analysis of the study.
Larry Glass, Chief Science Officer, Neuren Pharmaceutical
At the 6th Annual Traumatic Brain Injury Conference in Washington DC.
http://tbiconference.com/home/index.php/newagenda
Larry Glass to present study in May
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.97 |
Change
0.000(0.00%) |
Mkt cap ! $2.552B | |||
| Open | High | Low | Value | Volume |
| $19.96 | $19.97 | $19.69 | $4.156M | 209.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 246 | $19.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.99 | 512 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |